# Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

> **NCT02157883** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 39 (actual)

## Conditions studied

- Advanced Non Small Cell Lung Cancer
- Advanced (Inoperable) Non Small Cell Lung Cancer

## Interventions

- **PROCEDURE:** Pharmacokinetic sampling
- **DRUG:** AZD9291
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT02157883
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-06
- **Primary completion:** 2015-04-03
- **Final completion:** 2023-05-17
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02157883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02157883, "Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02157883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*